Joseph Shaw

Joe is a Principal Scientist at AstraZeneca, where he leads the scientific direction of reagents and assays to advance small molecule projects within an Oncology portfolio. He has worked across new drug modalities in targeted degradation and induced proximity, and delivered programs from target idea to clinical candidates. He has a particular interest in unambiguous cell-based assays that measure specific events such as compound binding, or protein-protein interactions. His work also focusses on how such methods are deployed at DMTA-scale to inform Medicinal Chemistry design, to earlier phases of Hit-to-Lead and Hit Discovery where compounds are typically weaker, and how such methods are applied across a portfolio of numerous drug projects. Joe spends most of his time trying to deploy these methods to either novel, or well-known-but-undrugged targets, seeking to find or develop world’s first ligands.